TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05125952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viasys Avea Ventilator
Description: Measuring dynamic airway driving pressure and static airway driving pressure during pressure support breath, and static airway driving pressure during a volume control breath. Measuring airway occlusion pressure during pressure support breath.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips Respironics NM3 device
Description: Measuring static airway driving pressure during pressure support breath

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Servo U ventilator
Description: Measuring static airway driving pressure and p0.1 during pressure support breath.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vyaire SmartCath adult nasogastric tube with Esophageal balloon
Description: Measuring static and dynamic esophageal driving pressure during pressure support breath, and esophogeal pressure change during airway occlusion maneuver.
Study: NCT05517824

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: microinsulated needle radiofrequency
Description: A single treatment using a microinsulated needle radiofrequency device
Study: NCT05705115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer acetate
Description: Ringer acetate 5 ml/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer acetate
Description: Ringer acetate 5 ml/kg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure
Description: Lower body negative pressure, 40 mmHg. Experimental hypovolemia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower body negative pressure
Description: Lower body negative pressure, 40 mmHg. Experimental hypovolemia.
Study: NCT06416020

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HC-MOUD Only
Description: MOUD with buprenorphine provided in a hub buprenorphine clinic

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BT-MOUD with Buprenorphine
Description: MOUD with buprenorphine provided by a hub buprenorphine provider either in the hub clinic or via telemedicine at a community hub; Recovery Guiding provided to participants
Study: NCT05297929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan Tablet
Description: Drug: Irbesartan Oral administration on an empty stomach／fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan Tablet
Description: Drug: Irbesartan Oral administration on an empty stomach／fed condition
Study: NCT05581433

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Topical Cooling Spray
Description: The process of cooling the area to be injected with a cooling spray before the application in order to reduce the pain.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline spray as Placebo
Description: Application of saline spray without cooling effect to the area to be injected for placebo purposes
Study: NCT04571801

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard diagnostics
Description: Standard diagnostics (Microbial diagnostics by means of standard culture methods + optional consultation of experts in the field of infectious diseases) within the first 72 h after diagnosis of sepsis / septic shock

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Next Generation Sequencing (NGS)
Description: Standard diagnostics + NGS (Microbial diagnostics using standard culture methods + Next Generation Sequencing + optional consultation of experts in the field of infectious diseases) within the first 72 h after diagnosis of sepsis / septic shock
Study: NCT06214702

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: ELISA estimation of PLGF, sFlt-1 and Serpin C

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: ELISA estimation of PLGF, sFlt-1 and Serpin C
Study: NCT05049928

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation solution (m-Rehab)
Description: The telerehabilitation program consists of the following elements:~* Mobile applications and website usable on smartphone and tablet for the patient.~* Teleconsultation solution for the patient and the doctors.~* Video conferencing solution for professionals involved in patient follow-up: educators in adapted physical activity, physiotherapists, psychologists, dieticians, etc.~* Web interface for health professionals allowing the collection and monitoring of various parameters in physical activity and nutrition as well as progress in therapeutic education activities.~* Withings® connected objects
Study: NCT05391581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIPR antagonist / study tool
Description: Selective antagonist of the GIPR, GIP(3-30)NH2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIPR antagonist / study tool
Description: Selective antagonist of the GIPR, GIP(3-30)NH2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLP-2R antagonist / study tool
Description: Selective antagonist of the GLP-2R, GLP-2(3-33)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLP-2R antagonist / study tool
Description: Selective antagonist of the GLP-2R, GLP-2(3-33)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Saline

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Saline

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT06272045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENRICH
Description: In the ENRICH intervention, home visitors will incorporate heart health information and activities into routine home visits beginning in pregnancy and continuing until children turn 2 years old. The intervention includes 1) Information and resources on topics such as healthy eating, physical activity, weight management, tobacco use, healthy sleep and stress reduction, 2) tools like scales, Fitbits, and blood pressure monitors to facilitate self-monitoring, and 3) activities and information focused on infant nutrition, feeding, healthy growth, sleep, play and emotions and soothing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Home Visiting
Description: Usual home visiting without cardiovascular health promotion content
Study: NCT06598371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSQ-004EX
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSQ-004EX
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSQ-004EX
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Given by IV
Study: NCT04659629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NL-201
Description: NL-201 is a de novo protein therapeutic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NL-201
Description: NL-201 is a de novo protein therapeutic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NL-201
Description: NL-201 is a de novo protein therapeutic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NL-201
Description: NL-201 is a de novo protein therapeutic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection [Keytruda]
Description: A programmed death receptor-1 (PD-1)-blocking antibody
Study: NCT05350514

Intervention type: DRUG
Intervention: PI-2620 tracer
Description: Following published manufacturer guidelines for Flutemetamol (VizamylTM), Flortaucipir (TauvidTM) and PI-2620 tracer administration162, all participants will be given a 370 MBq (10 mCi) single intravenous bolus (total volume 10mL) of the radiotracer, followed with an intravenous flush of 0.9% sodium chloride injection. Radiotracer administration and participant monitoring will be conducted by trained personnel from the CU-RIC.

Intervention type: DRUG
Intervention: PI-2620 tracer
Description: Following published manufacturer guidelines for Flutemetamol (VizamylTM), Flortaucipir (TauvidTM) and PI-2620 tracer administration162, all participants will be given a 370 MBq (10 mCi) single intravenous bolus (total volume 10mL) of the radiotracer, followed with an intravenous flush of 0.9% sodium chloride injection. Radiotracer administration and participant monitoring will be conducted by trained personnel from the CU-RIC.
Study: NCT04659629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection [Keytruda]
Description: A programmed death receptor-1 (PD-1)-blocking antibody
Study: NCT04041479

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: iTBS rTMS targeting the DMPFC or left DLPFC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: iTBS rTMS targeting the DMPFC or left DLPFC
Study: NCT06621498

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ridge preservation technique
Description: Tooth extraction, deperiostation of the buccal and oral marginal gingiva, placement of d-PTFE membranes and suturing.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ridge preservation
Description: Tooth extraction, socket filling with PRP, deperiostation of the buccal and oral marginal gingiva, placement of d-PTFE membranes and suturing.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ridge preservation
Description: Tooth extraction, full-thickness graft harversting and socket sealing with it.
Study: NCT06618040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bedtime Stories Sleep Health Education Program for Caregivers (BTS-C)
Description: The BTS-C includes 6 educational modules on different topics related to sleep health: principles of healthy sleep practices include sleep routines, the sleep environment, considerations for screen time, timing of sleep and activities surrounding sleep, expectations for healthy sleep and sleep duration. Caregivers will also receive a combination of tailored messages or prompts to explore progress, identify strategies for change, and goal setting.
Study: NCT06619119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Excape room simulation
Description: Application of Research:~Preparation and Implementation of the Escape Room The escape room game scenario prepared by the relevant faculty members consists of the subjects of Triage, Basic Life Support, Advanced Life Support and Traumas, which are included in the Emergency Nursing course curriculum. Students who will participate in the escape room game were given 30 minutes to solve the puzzles in the room, follow the clues, find the exit key and escape. To solve puzzles, unlock padlocks, and find specific objects in the escape room, students had to answer questions on Triage, Basic Life Support, Advanced Life Support, and Traumas and manage to exit the room in time.
Study: NCT06620250

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Digital Prevention and control of myopia
Description: The Digital Intervention Programme for parents/primary caregivers is primarily a digital intervention to address the attitudes, knowledge and actions of parents or primary caregivers of pre-school children regarding the prevention and control of myopia.
Study: NCT06631846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Participants in the music therapy group (MTG) will be comfortably lying on the bed in a reclined position of 30-45 degrees. Using a headphone, participants will be instructed to select a volume that is comfortable to their ears and listen to the music titled as The Best Relaxing Piano and Flute Music Ever which will be played for 30-minutes every day for 1-week. Patients will be encouraged to focus on the music and let it fill their senses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Description: Mindfulness meditation group (MGT)will be listening to audio of Guided Mindfulness Meditation Series 1 by Jon Kabat-Zinn. Similar to MTG, participants in MMG will be lying on the bed in a reclined position of 30-45 degrees. A headphone to listen to the audio of guided MM will be provided to all the participants. Participants will begin with relaxation technique by focusing on deep breathing to help calm their body and mind. This will be followed by focusing on the present moment, letting go of any thoughts or distractions that come up. Participants can focus on their breath, bodily sensations, or a specific object in their environment. Finally, the session will end by expressing a gratitude for their body and mind and setting an intention to carry the feelings of relaxation and mindfulness with them throughout the day. Similar to MTG, MMG will engage in 30-minutes of MM every day for 1-week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy and mindfulness meditation
Description: Music therapy and mindfulness meditation group will be receiving both music therapy and mindfulness meditation in the same body position as MTG and MMG. Firstly, participants will listen to MT for 30-minutes followed by MM for another 30-minutes. In between the 2 interventions, a 15-minute of break will be provided to all participants. Intervention will be carried out every day for 1-week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac rehabilitation
Description: Control Group will not receive any other therapy except the conventional post-operative cardiac rehabilitation. Other 3 intervention groups will also be participating in the usual cardiac rehabilitation program. Cardiac rehabilitation will be conducted during phase I, where rehabilitation will focus on early mobilization and ambulation of participants with a target heart rate of resting heart rate + 30 beats, with the non-strenuous exercises in the bed or at the bedside, focusing on a range of motion and limiting hospital deconditioning.
Study: NCT06730802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitor
Description: the experiment group will receive first PCSK9 inhibitor before CABG, then twice a month until 3 months later.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Statin
Description: the control group will receive standard statin therapy.
Study: NCT06731114

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suboccipital muscle release
Description: Suboccipital muscle release.6 consecutive sessions for 2 weeks~• Frequency:( 3mins 3 reps) 9 mins .12 sessions in total

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suboccipital muscle release
Description: Suboccipital muscle release.6 consecutive sessions for 2 weeks~• Frequency:( 3mins 3 reps) 9 mins .12 sessions in total

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: TENS and hot pack for 10 mins 6 days a week for consecutive 2 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: TENS and hot pack for 10 mins 6 days a week for consecutive 2 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sternocleidomastoid release
Description: Frequency: 5 mins of SCM release and 9 mins (3 mins 3 reps )of suboccipital release. 12 sessions in total.
Study: NCT06731218

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RGB-5088
Description: Transplantation under the anterior rectus sheath
Study: NCT05262712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibro-tactile stimulation
Description: Vibro-tactile stimulation will be administered to the feet of participants via C2 tactors (diameter: 3.05 cm, height: 0.79 cm, operating frequency: 200-300 Hz see https://www.eaiinfo.com/tactor-info/). Vibro-tactile stimulation will be triggered by force-sensing resistors (TEA CAPTIV T-SENS FSR, see https://www.teaergo.com/products/tea-captiv-t-sens-fsr/).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Devices mounted, no stimulation
Study: NCT06730867

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR Therapy Protocol
Description: The intervention involves an eight-week program that details a specific EMDR protocol and questionnaire for people living with HIV. The EMDR sessions occur once a week for eight weeks under the supervision of the investigator.
Study: NCT06730295

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Online adaptive SBRT
Description: Online adaptive SBRT (without PTV expansion margin). The total dose will be 39-42Gy/3 fractions, administered once daily. FBCT and 4DCT will be acquired.
Study: NCT06477835

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SIM0718 Injection
Description: Subjects who meet entry criteria will be randomized in a 1:1 ratio to receive either SIM0718 or matching placebo,Q2W, SC until Week 16. At the Week 16 visit, subjects in the placebo group will be transferred to SIM0718 300 mg Q2W after completing safety and efficacy assessments. Subjects who were originally treated with 300 mg Q2W of SIM0718 will continue on their original treatment regimen.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SIM0718 Injection
Description: Subjects who meet entry criteria will be randomized in a 1:1 ratio to receive either SIM0718 or matching placebo,Q2W, SC until Week 16. At the Week 16 visit, subjects in the placebo group will be transferred to SIM0718 300 mg Q2W after completing safety and efficacy assessments. Subjects who were originally treated with 300 mg Q2W of SIM0718 will continue on their original treatment regimen.
Study: NCT05215912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNB-738
Description: TNB-738 is an investigation drug. Other: Matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNB-738
Description: TNB-738 is an investigation drug. Other: Matching placebo
Study: NCT04940715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive joint mobilization
Description: Dosage: 5 sets of 2 minutes with 30 seconds of rest were applied, with a strong force (\>50% of maximum therapist strength), according to patient's irritability and severity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization with movement
Description: Dosage: 3 sets of 10 repetitions were performed, with 1-2 minutes of rest between sets.
Study: NCT05564650

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT04041479

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: iTBS rTMS targeting the left DLPFC
Study: NCT05851924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NALIRIFOX
Description: Patients will receive NALIRIFOX for a total of 4 months. NALIRIFOX will be administered on days 1 and 15 of a 4-week cycle for 4 cycles until completion of therapy, intolerable toxicity, or until the development of criteria for removal from the study.~Liposomal irinotecan: 50 mg/m2 IV over the course of 90 minutes (±10 minutes) on days 1 and 15 of every 4-week cycle.~Oxaliplatin: 60 mg/m2 IV over the course of 120 minutes (±10 minutes) on days 1 and 15 of every 4-week cycle.~Leucovorin: 400 mg/m2 IV over the course of 30 minutes (±5 minutes) on days 1 and 15 of every 4-week cycle.~5-FU: 2400 mg/m2 IV over the course of 48 hours (or until the infusion is complete) on days 1 and 15 of every 4-week cycle

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AD-XRT and Capecitabine
Description: The interval between completion of induction chemotherapy and initiation of AD-XRT will be 2-6 weeks. The patient will be concurrently treated with capecitabine (1000-1500 mg flat BID PO Monday to Friday) with radiation, as per standard dosing regimens at MSK.
Study: NCT05564650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT05350514

Intervention type: DRUG
Intervention: PI-2620 tracer
Description: Following published manufacturer guidelines for Flutemetamol (VizamylTM), Flortaucipir (TauvidTM) and PI-2620 tracer administration162, all participants will be given a 370 MBq (10 mCi) single intravenous bolus (total volume 10mL) of the radiotracer, followed with an intravenous flush of 0.9% sodium chloride injection. Radiotracer administration and participant monitoring will be conducted by trained personnel from the CU-RIC.
Study: NCT06591767

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: 200 mg supplemental Quercefit®

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Berberol K®
Description: Berberine Phytosome® 730 mg~+ MonakoPure® containing 2.9 mg of monacolin K and KA from red yeast rice extract

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Berberol K®
Description: Berberine Phytosome® 730 mg~+ MonakoPure® containing 2.9 mg of monacolin K and KA from red yeast rice extract
Study: NCT05085808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone
Description: Trazodone will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the trazodone arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Quetiapine will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the quetiapine arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the placebo arm.